Your Validation Engine for AI Drug Discovery

Customer Reviews

Latent Labs
Simon Kohl
Founder & CEO

Latent Labs combines AI-first design with internal wet-lab expertise. External partners like GenScript add valuable capacity for validation at scale, their ability to rapidly express, test, and validate our AI-designed sequences allows us to complement our internal capabilities and close the loop between computation and biology — turning theoretical designs into real-world drug candidates with unprecedented speed and precision.

Viiv Healthcare
Dr. Tiancen Hu
Scientific Director

The TurboCHO™ system of GenScript has dramatically accelerated the engineering and optimization of our biologics programs including multispecific modalities. The throughput, quality and turnaround time are top notch in industry, routinely providing us hundreds of purified bispecific antibodies with high purity, low endotoxin, high yield (enough for both functional and mouse PK study from 20 ml culture!) and even normalized concentration. All these can happen within a few weeks after we submit the sequences. To us, this is a game changer especially in the era of AI/ML-aided protein engineering.

Twain Therapeutics
Dr. Yuankai W.
Senior Director

Twain Therapeutics engaged GenScript to support developability assessment across our multispecific antibody portfolio. The thermal stability and purity analyses were performed to a high standard and delivered on the promised timeline. Their scientists were responsive and collaborative from study design through data review, and the final reports were clear, well‑organized, and easy to hand off to project teams. The work accelerated down‑selection and de‑risked our next experiments. We look forward to partnering with GenScript again.

Case Studies

• 178 AI-Designed GFPs Expressed & Assayed in 8 Days via E. coli HTP Platform
  

  
  

  • GenScript confirmed the functionality of ESM3's AI-designed esmGFP - a novel protein created by simulating 500 million years of evolution - through high-throughput E. coli expression.
  • We delivered expression and assay services for 178 AI-generated GFP variants in just 8 business days, setting a new benchmark for rapid validation of computationally designed proteins.

  Featured on the cover of Science’s February issue in 2025.
  Hayes, Thomas, et al. Simulating 500 Million Years of Evolution with a Language Model. Science387,850-858(2025).
  https://www.science.org/doi/10.1126/science.ads0018

• Cell-Free Expression Bundled with BLI Screening Powers Latent-X AI Model for Latent Lab

  The Challenge

  Latent Labs needed to experimentally validate their Latent-X AI model, which designed 100 de novo mini-binders against five different therapeutic targets. They required a "build and test" partner to translate these digital designs into functional in vitro binding data at scale.

  The Solution: GenScript's "Build & Test" Platform

  GenScript provided an end-to-end service to bridge the in silico to in vitro gap.

  • Build: GenScript synthesized and codon-optimized 100 mini-binder designs for each target using Cell-Free expression. Key target proteins (BHRF1, MDM2, MCL-1) were produced via GenScript's E. coli expression service.
  • Test: All binding analysis was performed by GenScript on an Octet RED3844. This included HT-BLI for rapid screening of all 100 designs per target and 5-concentration BLI for precise affinity determination.

  The Outcome

  GenScript's platform provided the core in vitro data that validated the Latent-X AI model. The results confirmed high experimental hit rates (e.g., 64% on BHRF1 ) and potent, high-affinity binders in the low-nanomolar to picomolar range, proving the model's superior performance.

  Preprint: "Latent-X: An Atom-level Frontier Model for De Novo Protein Binder Design"

  https://doi.org/10.48550/arXiv.2507.19375

• Cell-Free 4-Day Cycle for AI-Ready Dataset through 384-Well Plate Expression
  • Fast and Reliable Workflow – GenScript’s 4-day integrated sequence-to-data process enables rapid, consistent validation of AI-generated sequences at scale.
  • Controlled Variability – 384-well cell-free expression and Carterra LSA assays deliver reproducible results, with production variability <10% and assay response variation <25%.

  

  

  
• 500 AI-Designed IgGs Expressed & Customized Assayed in 15-Business-Day via TurboCHO HTP Platform.

  Project Background:

  • The in vivo discovery team focuses on a new pipeline for antibody discovery and screening.
  • A total of 500 human IgGs need to be expressed and validated via customized affinity binding assays (Carterra LSA) and cell-based binding assays (FACS).
  • Except for the customized datasets, an extra 100 ug of each sample must be returned.

  Results:

  • Average Yield: 125mg/L and SEC-HPLC Purity: 90%
  • Total timeline: 15BDs including 3 key customized steps (assay protocol + AI-ready report + sample delivery)
  • Rapid customization of AI drug discovery process to achieve fast 15 BD delivery timeline

  

  

  
• Cell-Free Expression Bundled with Affinity Ranking and Characterization Delivered in 14 Days

  A set of 500 AI-derived variants across five targets was evaluated using an integrated sequence-to-data workflow for rapid hit discovery. Variants were generated and expressed using a proprietary cell-free system, enabling protein production within hours, and directly advanced into high-throughput BLI screening. Initial binders were identified across all targets within 4 days, with hit rates ranging from ~6.9% to ~46.5%.

  Selected hits were scaled up, purified, characterized by 5-point BLI, and the top candidates were subsequently subjected to SPR kinetic analysis. Expression performance remained strong throughout, with average yields of 1.64 mg/mL, maximum yield of 712 μg/mL (CFPS), and >85% purity observed in 95% of variants.

  This workflow enables progression from AI-designed sequences to validated binding data in just 14 days, accelerating confident hit selection in early discovery.

  

  

  

  

  ✔ 5mL Cell free expression + Ni purification

  ✔ Average Yield: 1.64mg

  ✔ Highest Yield: 712 µg/mL CFPS

  ✔ 95% variants were observed > 85% purity by SDS-PAGE

  
• Multi‑Assay Platform Enables Reproducible, Scalable Hit Validation and Characterization
  • Validation assay list and risk assessment

  

  • The LSA platform provides both the throughput required for large-scale screening and the precision required for downstream lead characterization.

  

  • Strong correlation and high reproducibility was observed across orthogonal analytical methods, supporting reliable developability assessment and candidate differentiation.

  

  

  
• Affinity Binding Solution Comparison across SPR, BLI, and Carterra LSA

  In this study, binding affinities (KD) were measured using SPR, BLI, and LSA to assess cross-platform consistency.

  Results showed that KD values from BLI and LSA closely matched those from SPR across different affinity ranges, demonstrating strong agreement in binding measurements.

  These results validate BLI and LSA as reliable, high-throughput alternatives to SPR, enabling flexible platform selection without compromising data accuracy.

  

  

  

  Biacore 8K SPR

  

  Octet BLI

  

  Cartrerra LSA